Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer

R. J. Morgan, J. H. Doroshow, L. Leong, J. Schriber, S. Shibata, S. Forman, V. Hamasaki, K. Margolin, G. Somlo, J. Alvarnas, M. McNamara, J. Longmate, J. Raschko, W. Chow, S. Vasilev, K. McGonigle, Y. Yen

研究成果: 雜誌貢獻 › 文章 › 同行評審